anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to a system and to a computerised method for remote monitoring, analysis and prediction of the condition of a patient by a sequence of electrocardiograms (ECG). For each patient from the observed plurality, the sequence of their ECGs marked with the identifiers of the patient is therein accumulated in a database. At the request of the doctor, a subset of the ECGs is isolated followed by combining into a target group according to the identifiers of the patient and in accordance with the restrictions specified in the request of the doctor. The isolated subset is clustered by means of combining the ECGs into a cluster on the basis of mutual similarity of shapes thereof. The degree of similarity of shapes is determined in the space of indicators of ECG shapes. Each ECG is associated with a discretised ECG (DECG) constituting a point with coordinates the values whereof carry information about the shape of the original ECG. The measure of similarity of shapes between pairs of ECGs is defined as the distance between the corresponding pairs of DECG points. For each cluster, a standard is formed by forming DECG points corresponding to the ECG of the cluster. The condition of the patient is assessed by comparing the condition of the patient with the condition corresponding to the assigned standard. The change in the condition of the patient is assessed by the change over time of the distances between each of the newly supplied DECGs and the assigned standard. The condition of the patient is predicted based on the &#34;observation history&#34; relative to the assigned standard. The condition of the patient is visualised in form of the dynamics of change of the distances of the newly supplied ECGs when the geometric paths of movement move between the assigned standards.EFFECT: increased accuracy of automated assessment of the condition of the patient is achieved.20 cl, 4 dwg, 1 ex
NEW MATERIAL:The compound of formula I (Az is imidazolyl or triazolyl; R is H or alkyl; R&lt;1&gt;-R&lt;3&gt; are H or halogen) or its salt. EXAMPLE:1-(4-Fluorophenyl)-1-(isoxazol-3-yl)-2-(1H-1,2,4-triazol-1-yl) ethanol. USE:A medicine for human or animal. An antimycotic agent for oral administration or injection or an agricultural or industrial fungicide. PREPARATION:A compound of formula I wherein R&lt;3&gt; is H can be produced by reacting an acid chloride of formula II with a (substituted) benzene of formula V in the presence of a Lewis acid catalyst such as AlCl3 at 0-100 deg.C, subjecting the resultant compound of formula III to oxirane-formation reaction to obtain an ethylene oxide of formula IV and reacting the oxide with the compound of formula M-Az (M is H or alkali metal). The obtained compound of formula I can be converted to another compound of formula I wherein R&lt;3&gt; is halogen by halogenation.
Bruxism is a common parafunctional habit defined as clenching and/or grinding of teeth occurring during sleep and/or wakefulness. Although the etiology is not known exactly, there is a consensus that it is multifactorial. Emotional stress is one of the important factors leading to bruxism. It has been shown that a stressful life has an important effect in explaining clenching during the day. In addition to stress, previous studies showing that psychiatric disorders, especially depression and anxiety disorders, accompany TMD and bruxism.

This trial aimed to examine the effects of manual therapy and home exercise treatments on pain, sleep quality, stress level and quality of life in patients with bruxism. In the study thirty bruxists over the age of 18 were included in the research protocol. The patients were randomly divided into Manual Therapy Group (MTG) and Home Exercise Group (HEG). Before treatment (T1) demographic information was obtained from all patients, they were asked to fill out the Pittsburgh Sleep Quality Index (PSQI), Perceived Stress Scale (PSS), Fonseca Anamnestic Index (FAI) and Quality of Life Scale/Short Form-36 (SF-36) and number of trigger points and pain levels were determined at baseline. Manual therapy and home exercises were applied to both groups for 8 weeks and all tests were repeated and re-evaluated at the end of 8 weeks (T2). The normal distribution of the groups was tested with Kolmogorov-Smirnov. Paired Samples t test was used for intra-group comparisons at T1 and T2, and Independent t test was used for inter-group comparisons. The statistical significance level was accepted as p\&lt;0.05.
&lt;P&gt;PROBLEM TO BE SOLVED: To ameliorate skin trouble such as various phenomena supposed to be caused by active oxygens, e.g. skin roughening, melasmas, dry skin, ephelides, or atopic dermatoses.  &lt;P&gt;SOLUTION: An antioxidizing skin lotion including a vitamin C glycoside is provided. The state of skin can be improved to achieve beautiful skin by continuously applying the antioxidizing skin lotion to a face or hand skin. Furthermore, prophylaxis of the skin roughening can be carried out.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new angiogenesis-inhibiting agent effective for the inhibition of angiogenesis in various diseases, safe and having a highly practical utility, and a method for screening the same.  &lt;P&gt;SOLUTION: This angiogenesis-inhibiting agent contains an active ingredient consisting of ansamycin-based antibiotic substances such as rifampicin, rifamycin SV or 3-formylrifamycin which are conventionally used as antibacterial agents for the treatment of tuberculosis and Gram-positive bacterial infection. The active ingredient has an excellent angiogenesis-inhibiting activity. The angiogenesis-inhibiting agent is effective for inhibiting the angiogenesis accompanying with malignant tumor, diabetic retinopathy, retinal angiogenesis and inflammatory diseases, and inhibiting the angiogenesis accompanying cardiovascular remodeling, and can be used as the treating agent for each of the diseases. The method for screening the agent enables an effective screening of the angiogenesis-inhibiting agent by detecting an angiogenesis-inhibition signal based on a gene expression.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
An apparatus that includes a surgical telescopic device having a distal end and a proximal end; a camera coupled to the proximal end of the surgical telescopic device; and a holographic notch filter interposed between the camera and the proximal end of the surgical telescopic device. The camera preferably is a charge-coupled-device camera (&#34;CCD camera&#34;). The apparatus may also include a focusing lens or an alternative type of filter such as long-pass filter or an infrared filter. The surgical telescopic device may be used by illuminating the material with non-white light and detecting the emitted fluorescence, phosphorescence or luminescence. Specifically, the invention relates to apparatuses and methods for detecting (and imaging) fluorescent, phosphorescent or luminescent material in a host. The invention further relates to a method for identifying cancer tissue or tissue containing atypical cells of an individual.
328,111. Risler, J. Dec. 13, 1928, [Convention date]. Salves; medicinal powders for external use.- Creams or other preparations such as soaps or &#34; poudres de riz,&#34; for protection of the skin against ultra-violet light consist of the usual ingredients togetlier with cadmium sulphide. The cadmium sulphide used may contain also zinc sulphide, or other ingredients such as sodium hyposulphite, zinc sulphate, copper bismuth or manganese. As an example a cream with a red phosphorescence consists of neutral 30 per cent glycerine 66 grammes, purified stearic acid 16 grammes, solution of ammonia B.P. 6 grammes, distilled water 8 grammes, 30 per cent phosphorescent cadmium sulphide 4 grammes. By reducing the strength of the phosphorescent cadmium sulphide to 20 per cent and 12 per cent the cream can be made of orange or citron yellow respectively. Perfumes may be added. Fluorescent aniline dyes may also be added and minute quantities of radio-active substances such as radium bromide in extremely dilute solution. Known preparations containing phosphorogenic copper together with zinc sulphide and in some cases the further addition of manganese are referred to.
The present invention discloses kidney tonifying marrow facilitating food tea and a preparation method thereof. The kidney tonifying marrow facilitating food tea is mainly prepared from green tea, milkvetch seed fructus tribuli, dodder and black bean according to certain mixture proportions by weight. The present invention develops and perfects the traditional tea to properly add foods as auxiliary materials into the tea according to the thought that &#39;tea is predominate, foods are auxiliary&#39;. The kidney tonifying marrow facilitating food tea is made by adopting a unique production process, and nutrient components of the tea and nutrient components of the foods are increased to correct the biasedness and make up for the deficiencies on the premise that the original efficacy of the tea and the foods is maintained. The food tea performs the functions of tea drinker&#39;s physical function enhancement, liver and kidney nourishment, vigor facilitation and marrow tonifying. The food tea avoids a potential impact caused on a human body by tea drinking.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an active ingredient highly safe in administration to a human body, and exhibiting excellent bioactive effects; and to provide a food containing the active ingredient.  &lt;P&gt;SOLUTION: The inhibitor of colon cancer contains a glucosylceramide fraction extracted from a plant as the active ingredient. Preferably, the inhibitor of the colon cancer contains the glucosylceramide fraction extracted from cereals as the active ingredient. The inhibitor of the colon cancer prevents the onset of the colon cancer. The food is obtained by formulating the inhibitor of the colon cancer.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
A multivalent immunoglobulin which comprises at least three linked antigen binding domains each of said domains being specific for a complementary site on a cytokine, (e.g. TBF- alpha , TNF- beta , an interleukin, an interferon, such as IFN- gamma , or/and a colony stimulating factor) and characteristically interacts with the cytokine to neutralise its biological activity. The multivalent immunoglobulins have surprisingly increased neutralising activity and are useful for therapeutic or prophylactic treatment of conditions involving undesirably elevated levels of cytokine. Preferably the multivalent immunoglobulin comprises from 4 to 20 antigen binding domains, which are especially of class IgG. The multivalent immunoglobulin may comprise recombinant immunoglobulin molecules and fragments thereof, and the antigen binding domains may be covalently or non-covalently linked. &lt;IMAGE&gt;
This invention is directed to construction of recombinant plasmids that contain the Epstein-Barr virus (&#34;EBV&#34;) genetic information involved in the immortalization of human lymphocytes, but that lack one or more genes implicated in EBV lytic replication. The recombinant plasmids have the advantage of being able to immortalize human lymphocytes, while being incapable of generating infectious EBV particles. The invention also provides human lymphocytes that have been successfully infected and immortalized by the recombinant plasmids. These human lymphocyte clones can be used as cellular factories to produce desired proteins and as delivery vehicles for gene therapy. Additionally, the invention establishes a method by which desired proteins can be produced in immortalized cellular factories, without generating infectious EBV particles. These proteins can be the normal cellular products of immortalized human lymphocytes, or they can be proteins encoded by foreign genes, which have been cloned into the lymphocytes.
PURPOSE:A cholagogue having high safety and durability of action, containing cinnamic aldehyde as an active ingredient. CONSTITUTION:A cholagogue containing cinnamic aldehyde, a main component of cinnamon oil, as an active ingredient. After cinnamic aldehyde (A) is compared with sodium dehydrocholate (B) in terms of cholagogic action (by Wistar male rat) and acute toxicity (by -Y male mouse) and discussed, B has temporary effect in cholagogic action, and A has excellent cholagogic action and durability. A has &gt;=5,000mg/kg LD50 value, B has 2,050mg/kg LD50 value. A is observed to have high cholagogic action and high safety. An effective dose of cinnamic aldehyde is properly regarded to be 50-100mg per time adult and &lt;=3 times administration daily.
Correctly formulated enterically coated nutrient pellets are able to significantly to lower the blood sugar level of type two diabetics when administered with a normal meal. The inventive composition is effective at dosage levels of 10 g or less. Effective doses of the composition contribute 42 kcal or fewer to the patient&#39;s diet. A preferred form of the composition contains lauric acid coated for release in the distal bowel. When taken with an ordinary meal, the effective dosage does not induce the ileal brake and is more than 50 times (often more than 100 times) as effective on per kilocalorie basis as an ordinary meal at eliciting increases in PYY and GLP-1. Thus, ordinary nutrients—as opposed to drugs—can be used to reduce blood sugar levels when administered at dosage levels that are not significant promoters of weight gain.
PURPOSE:To obtain the titled cosmetic, containing a higher fatty acid salt, colloidal hydrous silicate and further a compound selected from aldonic acid and aldonolactone and having excellent usability and emulsion stability. CONSTITUTION:The titled cosmetic containing a higher fatty acid salt (preferably Na, K and triethanolamine salt) expressed by formula I (R is 11-21C straight-chain or branched alkyl or alkenyl; M is alkaline metal, ammonium, alkanolamine, etc.), a colloidal hydrous silicate (e.g. montmorillonite) and further one or two or more selected from aldonic acid (preferably gluconic acid) and aldonolactone (preferably glucono-delta-lactone) expressed by formula Il (n is &gt;=3). This cosmetic is capable of exhibiting the same weak acidity as that of skin surface and simultaneously has excellent emulsion stability. The aldonic acid, etc., are preferably dissolved in water and added before previous emulsification from aspects of preventing smell from changing.
PROBLEM TO BE SOLVED: To obtain a stabilized crosslinkedpolyvinyl pyrrolidone iodine complex having antimicrobial activity without stimulation to wound and retardation of wound healing. SOLUTION: An aqueous iodide solution containing iodine and iodide ion is prepared. The molar ratio of the iodide to iodine exceeds 1/1 in the iodine solution, preferably &gt;=3/2. Then, crosslinked polyvinyl pyrrolidone is added to the iodide solution to allow them to react with each other at an ambient temperature. The content of effective iodine is 0.2-50wt.%. The crosslinked polyvinyl pyrrolidone-iodine complex can be used in a variety of topical antimicrobial products in the form of powder, aerosol spray, gel, cream, ointment and water-sensitive film. It can be applied to small wounds, incised wounds, scratches and burns in order to prevent infection and promoting their healing. In addition, it can also be used in other microbial infections on skin such as athlete&#39;s foot. This complex is insoluble in water, but water-absorbent and water-expansible.
PURPOSE:To obtain the extract of MANNENTAKE (Fomes japonicus, a kind of fungi) composed of the solvent extract of the mycelia of MANNENTAKE cultured in a specific medium or of the concentrate of the culture liquid after the separation of the mycelia, positive to ninhydrin reaction and Fehling reaction, etc., and containing the component resembling closely to the natural fruiting body of MANNENTAKE. CONSTITUTION:The seed mycelia of MANNENTAKE is cultured in a liquid medium containing 0.2-10W/V% glucose and 0.2-2W/V% wheat embryo. The cultivation is carried out by inoculating about 5-10mg of the mycelia to 100ml of the liquid medium, and stirring the medium at 200-300rpm and 25-30 deg.C under aeration of 0.5- 3.0V.V.m. in a dark place for 7-21 days. After cultivation, the cultured product or the mycelia separated from the cultured product is extracted with a solvent, or the cultured liquid left after the separation of the mycelia therefrom is concentrated to obtain the objective extract of MANNENTAKE. The extract is relatively stable at about &lt;=60 deg.C, contains the components having close resemblance to the natural fruiting body of MANNENTAKE, and exhibits excellent effect such as nutrient, tonic, brain refreshing, anti-inflammatory, diuretic effects, etc. as a health food.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide medical charcoal being provided with sufficient adsorption and deodorization functions even in a small quantity and having guaranteed source and quality and a method for producing such medical charcoal and to specifically provide medical charcoal comprising activated bincho charcoal and a method for producing such medical charcoal.  &lt;P&gt;SOLUTION: Kishu bincho charcoal used as a charcoal material is coarsely crushed (within 4 meshes) with a ceramic knife. Steam at a temperature of between 500 to 1,300°C is sprayed to 50,000 g of the charcoal material with partial pressure of between 100 and 200 kPa for 5 to 30 minutes. The composition ratios of the steam gas are steam (H&lt;SB&gt;2&lt;/SB&gt;O) ranging from approximately 5 to 100 vol.%, carbon dioxide ranging from approximately 5 to 100 vol.%, and nitrogen ranging from approximately 0 to 95 vol.%. Subsequently, air at normal temperature is sprayed for approximately 1 to 10 minutes. These procedures are determined to be one set that is repeated 10 to 120 sets. After washing, the products are finely crushed to have a particle size (average diameter of 12 microns) appropriate for use as cosmetic using a ceramic knife.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To select an essential oil effective to improve a specific item of a particular person, by using a computerized magnetic resonance analyzer and an analytical instrument having equal efficiency to the analyzer. SOLUTION: According to this method, a mutual action of minute magnetic resonance patterns is judged by a computerized magnetic resonance analyzer and an analytical instrument having equal performance to the analyzer. An effective combination and a proper blend ratio are obtained from congeniality relationships of human constitutions and various material and of various materials. The computerized magnetic resonance analyzer reproduces normal patterns of the minute magnetic resonance patterns of human bodies and substances approximately and obtains an echo from a body to be analyzed. For instance, a person&#39;s hand (b) to be analyzed and a candidate substance (c) (essential oil) expected to be useful for improvement are placed and measured on a measurement plate (a) of the computerized magnetic resonance analyzer.  A reaction as a result of the measurement is expressed by sound or a chart graph.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an ideal cosmetic material for forming a duplicated eyelid without troubles such as discoloration, separation of a latex component, onset of allergy and the like.  &lt;P&gt;SOLUTION: The cosmetic material for forming the duplicated eyelid contains at least ≥50/w% synthetic latex in the whole latex component. Thus, sufficient adhesiveness is provided. The content of impurities such as proteins and the like is very small even though a natural rubber latex is included, so when discoloration occurs, it will be in a range of practical allowance and there is no separation of rubber particles from serum liquid. As the cosmetic material contains no allergic materials, it can be used without anxiety.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:To obtain an adenosine deaminase inhibitor showing improving action on coronary vessel and cerebrovascular circulation, preventing and treating action on renal disease, anti-inflammatory action, etc., having excellent inhibitory action on adenosine deaminase, comprising a specific adenosine derivative as an active ingredient. CONSTITUTION:An adenosine deaminase inhibitor comprises a compound of formula I [R1 to R3 are H or alkyl; R is H, lower alkyl, amino or halogen; X is H, alkyl, alkenyl, allyl, methacrylic, cycloalkyl, phenyl, group of formula II (Z is H, OH, etc.; Q is H or OH; A is CH2, direct bond, O, S, etc.), group of formula III, etc., with the proviso that one of R1 to R3 is alkyl] or its pharmaceutically acceptable salt (e.g. 2&#39;-O-methyladenosine) as an active ingredient. This medicine shows inhibitory effect on reduction in action of adenosine analog- based anti-cancer medicine or antiviral agent in chemotherapy of cancer and virus by administration of this medicine before administration of anti-cancer medicine or antiviral agent or by simultaneously administration.
Regardless of proximal cause, photoreceptor injury or disease almost invariably leads to the activation of Muller cells, the principal glial cells in the retina. This observation implies the existence of signaling systems that inform Muller cells of the health status of photoreceptors. It further suggests that diverse types of photoreceptor damage elicit a limited range of biochemical responses. In the retina, the genomic responses to both light damage and inherited photoreceptor degeneration involve a relatively small number of genes and the genes activated by these two insults overlap substantially with one another and with the genes activated by retinal detachment. Among the induced transcripts, those coding for endothelin2 (Edn2) are unusual in that they are localized to photoreceptors and are also highly induced in all of the tested models of photoreceptor disease or injury. Acute light damage also leads to a &gt;10-fold increase in endothelin receptor B (Ednrb) in Muller cells 24 h after injury. These observations suggest that photoreceptor-derived EDN2 functions as a general stress signal, that EDN2 signals to Muller cells by binding to EDNRB, and that Muller cells can increase their sensitivity to EDN2 as part of the injury response.
PROBLEM TO BE SOLVED: To provide a substrate film for pasting and a pasting material having improved softness, stretchability and skin deformation followability. SOLUTION: The substrate film for pasting has a thickness of 20-200 μm and contains (a) 100 pts.wt. of a hydrogenated block copolymer obtained by the hydrogenation of a block copolymer containing &gt;=2 polymer blocks A composed of a vinyl aromatic compound and &gt;=1 polymer blocks B composed of a conjugated diene compound, containing 5-50 wt.% polymer block A and having a glass transition temperature of &lt;=-20 deg.C and a number-average molecular weight of 50,000-150,000 as a whole, (b) 20-200 pts.wt. of a polyolefin resin and (c) 50-200 pts.wt. of a plasticizer. The pasting material is produced by forming an adhesive layer on the substrate film.
A stable and safe skin antiseptic solution comprises chlorhexidine, pharmaceutically acceptable salts of chlorhexidine (e.g. chlorhexidine digluconate), or a mixture thereof, dimethyl lauramide/myristamide, and water. Said solution is essentially free of coconut oil diethanolamine concentrate (&#34;cocamide DEA&#34;), a known carcinogen. The active antiseptic ingredient, chlorhexidine (or its salts), is a di(4-chlorophenyldiguanido) compound. The functions of dimethyl lauramide/myristamide in said solution include, but not limited to, an aesthetics enhancer, a foam stabilizer, a solubilizer, and a fragrance. Said solution is specifically formulated to be safe with a reduced risk of carcinogenicity, and be capable of producing a stable and long lasting foam. The active antiseptic agent is evenly distributed in said solution and in said foam, respectively.